Cell X Technologies has announced a strategic collaboration with BioLamina to integrate BioLamina’s Biolaminin® defined laminin reagents into the Celligent™ platform, with the goal of improving consistency and reproducibility in advanced therapy manufacturing. This partnership highlights the importance of combining advanced automation with standardized, high-quality reagents to create scalable, reliable, and GMP-compliant processes for next-generation therapeutic development. By incorporating BioLamina’s full-length, human recombinant laminin-521 and laminin-511 isoforms—offered in both research-use-only and GMP-compatible formats—into optimized automated workflows, the collaboration is set to streamline iPSC culture and differentiation while reducing operator-related variability.
Lynne Frick, CEO of Cell X Technologies, emphasized the company’s focus on enhancing automation in regenerative medicine by embedding best-in-class reagents within automated workflows that support process characterization, development, and manufacturing. She noted that the collaboration with BioLamina reflects a shared mission of lowering variability and boosting success rates, particularly during the critical shift from research phases into clinical applications.
Echoing this sentiment, Klaus Langhoff-Roos, CEO of BioLamina, highlighted the company’s commitment to standardization, reproducibility, and physiological relevance in order to improve patient outcomes and ultimately save lives. He added that working with Cell X Technologies provides an opportunity to demonstrate the value of their “full-length equals full-function” approach and how, when paired with advanced automation, it can drive consistency, predictability, and scalability in iPSC-based manufacturing.
The partnership demonstrates how Cell X’s walk-away automation and advanced imaging capabilities, combined with BioLamina’s rigorously developed reagents, create a unified solution designed for robust and regulator-ready workflows. Together, these complementary technologies provide the foundation for reproducible, reliable, and scalable cell therapy manufacturing. By bridging automation with high-quality biomaterials, the collaboration positions both companies to strengthen the regenerative medicine landscape and support the broader goal of delivering consistent, safe, and effective therapies to patients worldwide.
